BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioSimilar

Polpharma Biologics And Tuteur Sign Landmark LATAM Biosimilar Licensing Partnership

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a...

May 25, 2026 | News

Samsung Bioepis Launches First Ustekinumab Biosimilar In Japan With NIPRO

Ustekinumab BS 45 mg Syringe for S.C. Injection「NIPRO」 is now available in Japan, after its listing under the National Health Insurance (NHI) Drug ...

May 21, 2026 | News

IQVIA And Kexing Biopharm Advance Global Biosimilar Expansion Through AI Enabled Strategic Collaboration

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthc...

May 15, 2026 | News

Henlius And Organon Secure European Approval For First Pertuzumab Biosimilar POHERDY

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHE...

May 01, 2026 | News

Mabwell Secures JFDA GMP Compliance For Denosumab Biosimilars, Marking PIC S Milestone

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its wholly-owned subsidiary, T-m...

April 22, 2026 | News

Biocon Limited Launches Bosaya And Aukelso In The United States To Expand Bone Health Access

Bosaya™ and Aukelso™ (both denosumab-kyqq products) now available in the United States, following U.S. FDA approval in September 2025 with ...

April 10, 2026 | News

Yoshindo And Cytiva Strengthen Japan’s Biologics Sovereignty Through Scalable Modular Manufacturing

Strengthening Yoshindo’s domestic biosimilar manufacturing footprint Cytiva’s modular manufacturing platform to support Yoshindo wit...

March 25, 2026 | News

Prestige Biopharma Reports Phase 3 Success For HD204 Demonstrating Clinical Equivalence In Advanced NSCLC

Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung can...

March 25, 2026 | News

Samsung Bioepis And Sandoz Expand Global Biosimilar Alliance Across Five Assets

The agreement covers up to five assets, including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), for collaboration of development and ...

March 18, 2026 | News

Celltrion Expands US Immunology Portfolio With AVTOZMA Subcutaneous Tocilizumab Biosimilar

AVTOZMA® (tocilizumab-anoh) is among the first wave of tocilizumab biosimilars with both intravenous (IV) and subcutaneous (SC) formulations app...

March 17, 2026 | News

Cytiva Expands Fast Trak Process Development Facility In Bengaluru To Support India’s Biopharma Innovation

Cytiva has expanded its Fast Trak process development and training facility in Bengaluru, reinforcing its commitment to supporting India’s rapidly ad...

March 09, 2026 | News

SteinCares And Shilpa Biologicals Sign Strategic Licensing Agreement To Commercialise Biosimilar Across Latin America

New partnership combines Shilpa Biologicals' development and manufacturing capabilities with SteinCares' regional commercialization platform Collaborati...

February 26, 2026 | News

European Commission Approves Gotenfia® Biosimilar, Expanding Golimumab Access Across Europe

European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera and will be marketed b...

February 17, 2026 | News

Blau Farmacêutica Achieves End To End Development Of Pembrolizumab Biosimilar In Brazil

Blau Farmacêutica, a Brazilian pharmaceutical company listed on Brazilian Stock Market (B3) and a regional leader in hospital pharmaceuticals w...

January 27, 2026 | News

Stay Connected